Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost lipid nanocarriers versus latanoprost solution for male pattern hair loss
IRCT20211209053339N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of latanoprost in androgenetic alopecia (AGA), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Hair loss, Number of hair strands and 1 more. Started Jan 2022; status: completed.
02
Drugs
latanoprost
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT20211209053339N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211209053339N1.